{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:55:29Z","timestamp":1773154529457,"version":"3.50.1"},"reference-count":38,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,3,30]],"date-time":"2007-03-30T00:00:00Z","timestamp":1175212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytometry Part B Clinical"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background:<\/jats:title><jats:p>The success of treatment using monoclonal antibodies in oncology is influenced by, among other factors, the level of target antigen expression on tumor cells. The authors analyzed the intensity of the CD52 antigen expression in patients with chronic lymphoproliferative diseases and compared them with B\u2010lymphocytes of a healthy population and CD34<jats:sup>+<\/jats:sup> cells in peripheral blood stem cells (PBSC) grafts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Recently diagnosed and previously untreated patients with B\u2010cell chronic lymphocytic leukemia (B\u2010CLL), mantle\u2010cell lymphoma (MCL), or small lymphocytic lymphoma (SLL) were evaluated and compared with control group and CD34<jats:sup>+<\/jats:sup> cells. The intensity of CD52 was expressed in molecules of equivalent soluble fluorochrome units (MESF) and antibody\u2010binding capacity (ABC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>In the group of patients with B\u2010CLL, the CD52 level on tumor cells (245 \u00d7 10<jats:sup>3<\/jats:sup> MESF; 107 \u00d7 10<jats:sup>3<\/jats:sup> ABC) was significantly lower than on B\u2010lymphocytes of the control group (446 \u00d7 10<jats:sup>3<\/jats:sup> MESF; 194 \u00d7 10<jats:sup>3<\/jats:sup> ABC; <jats:italic>P<\/jats:italic> &lt; 0.001) and SLL tumor cells (526 \u00d7 10<jats:sup>3<\/jats:sup> MESF; 229 \u00d7 10<jats:sup>3<\/jats:sup> ABC; <jats:italic>P<\/jats:italic> &lt; 0.001). The CD52 antigen was expressed on a majority of CD34<jats:sup>+<\/jats:sup> cells, but its expression intensity was low (101 \u00d7 10<jats:sup>3<\/jats:sup> MESF; 44 \u00d7 10<jats:sup>3<\/jats:sup> ABC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Our data demonstrate differences in the intensity of the CD52 antigen expression between B\u2010lymphocytes and tumor lymphocytes of B\u2010CLL patients, and between B\u2010CLL and SLL tumor cells. CD52 antigen is expressed at low level on CD34<jats:sup>+<\/jats:sup> cells. \u00a9 2007 Clinical Cytometry Society<\/jats:p><\/jats:sec>","DOI":"10.1002\/cyto.b.20181","type":"journal-article","created":{"date-parts":[[2007,4,12]],"date-time":"2007-04-12T10:16:36Z","timestamp":1176372996000},"page":"363-370","source":"Crossref","is-referenced-by-count":17,"title":["Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B\u2010lymphocytes, CD 34<sup>+<\/sup> cells and tumor cells of patients with chronic B\u2010cell lymphoproliferative diseases"],"prefix":"10.1002","volume":"72B","author":[{"given":"Martin","family":"Klabusay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Sukova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Coupek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvona","family":"Brychtova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,14]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"3147","article-title":"Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma\u2010associated antigen","volume":"40","author":"Nadler LM","year":"1980","journal-title":"Cancer Res"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1721"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3389"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3554"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.06.119"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3270"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3951"},{"issue":"5","key":"e_1_2_5_9_2","first-page":"ECR13","article-title":"Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab","volume":"91","author":"Cheung WW","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198804000-00018"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.11.3691"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/14653240310004520"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.01.028"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2930633"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.11.6088"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.1990.tb01767.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.12.4684.bloodjournal88124684"},{"key":"e_1_2_5_18_2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V82.3.807.807","article-title":"Effect of CAMPATH\u20101H antibody on human haemapoietic progenitors in vitro","volume":"82","author":"Gilleece MH","year":"1993","journal-title":"Blood"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/332323a0"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404014"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1567"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-2061.x"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.7.2667"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2005.n.016"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3784"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(97)00158-6"},{"key":"e_1_2_5_27_2","first-page":"377","article-title":"Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors","volume":"52","author":"Sung C","year":"1992","journal-title":"Cancer Res"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0320(19981001)33:2<97::AID-CYTO3>3.0.CO;2-H"},{"key":"e_1_2_5_29_2","first-page":"305","article-title":"Removal of T cells from bone marrow for transplantation: Comparison of rat monoclonal anti\u2010lymphocyte antibodies of different isotypes","volume":"1","author":"Hale G","year":"1983","journal-title":"Mol Biol Med"},{"key":"e_1_2_5_30_2","first-page":"52","article-title":"The role of CAMPATH\u20101 antibodies in the treatment of lymphoid malignancies","volume":"26","author":"Dyer MJ","year":"1999","journal-title":"Semin Oncol"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1006\/immu.1994.1054"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404227"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200119"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290006125"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10428"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1309\/3G1XDX0DVHBNVKB4"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.990220208"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.2006.01986.x"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V73.6.1431.1431"}],"container-title":["Cytometry Part B: Clinical Cytometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcyto.b.20181","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cyto.b.20181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T18:06:50Z","timestamp":1697479610000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cyto.b.20181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,14]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1002\/cyto.b.20181"],"URL":"https:\/\/doi.org\/10.1002\/cyto.b.20181","archive":["Portico"],"relation":{},"ISSN":["1552-4949","1552-4957"],"issn-type":[{"value":"1552-4949","type":"print"},{"value":"1552-4957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,14]]}}}